While world public health agencies are focused on how to react to the next pandemic once it has started, a new plan proposes using ecological perspectives to prevent disease outbreaks before they happen.
A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial.
The inflammatory response from adaptive immune cells – such as B and T lymphocytes – clears the body of the SARS-CoV-2 virus, but at the same time, it also causes the characteristic symptoms of COVID-19, a new study finds.
Cornell researchers have identified a shift that occurs in canine coronavirus that points to a possible pattern of change found in other coronaviruses and which may provide clues to how they transmit to humans from animals.
A team has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including omicron. Their discovery could lead to more potent vaccines and new antibody-based treatments.
New research used engineered mice to compare SARS-COV-2 omicron subvariants, and found one of them, BA.5, was more virulent likely due to its ability to rapidly replicate early during infection.
During the COVID-19 pandemic, many U.S. hospitals had overcapacity intensive care units while other area hospitals had open ICU beds available, a phenomenon known as “load imbalance.”
Colleges and universities that imposed COVID-19 vaccine mandates for students in the fall 2021 semester averted 11% of cases and reduced deaths by 5% in the surrounding communities, according to new research.
The Cornell Veterinary Dance Collective Spring 2022 Showcase, aptly named “The Revival,” marked the group’s first return since the coronavirus pandemic stoppered such performances two years ago.